
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc has recently improved its financial position through equity financings and option exercises, achieving a notable increase in financing income, which rose to $284K for the quarter and $611K year-to-date. The company has made significant strides in preparing for the full launch of its LIBERTY Endovascular Robotic System, including expanding its commercial capabilities and receiving positive feedback from healthcare providers, indicating strong market potential. As Microbot Medical positions itself for accelerated growth with upcoming product launches and has established critical partnerships to enhance operational readiness, its competitive market stance could justify a premium valuation as it approaches key milestones.
Bears say
Microbot Medical Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to delayed commercialization of its LIBERTY Endovascular Robotic System and slower-than-expected market acceptance. The company also encounters risks relating to its inability to expand into neuro and cardio cases, setbacks in securing international regulatory approvals, and persistent reimbursement headwinds, all of which may hinder its growth potential. Moreover, the lack of profitability in the near term and the erosion of hospital margins due to the cost of its device further amplify concerns about the company’s financial sustainability.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares